LifeVantage (LFVN) investor relations material

Company transformation and business model

• Transitioned from traditional retail to direct sales, leveraging independent consultants as storytellers to drive growth and expand internationally, now operating in nearly 20 countries with a focus on further LATAM expansion.

• Built a $200 million business by emphasizing both product efficacy and income opportunities for consultants.

Scientific foundation and product development

• Core focus on nutrigenomics, with products designed to activate the body’s natural processes using natural ingredients, supported by over 30 peer-reviewed clinical studies.

• Rigorous five-pillar product vetting: nutrigenomic activity, proven efficacy, demonstrable benefits, delightful user experience, and daily use for habit-building and subscription predictability.

• Product development includes cell studies, ingredient synergy testing, and double-blind, placebo-controlled human clinical trials.

Innovation and future pipeline

• Maintains an 18-month cadence for major product launches, with upcoming releases targeting new health areas beyond the gut microbiome.

• Recent launches include a liquid collagen and a GLP-1 product, both meeting the five-pillar criteria.

• Acquisition of LoveBiome expanded the portfolio in the gut health space, with all products vetted for alignment with company standards.